PDCD1 and cancer: These drugs are effective in more than 25 types of solid cancers and multiple liquid malignancies.14,15 However, response rates to anti-CTLA-4 and anti-PD-1 therapies vary by cancer type with upper limits reaching only 40% in melanoma and lung cancer.